John Renger - Feb 9, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Feb 9, 2022
Transactions value $: -$662,500
Form type: 4
Date filed: 2/11/2022, 05:46 PM
Previous filing: Dec 28, 2021
Next filing: Mar 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$87.5K	+25K	+1262.63%	$3.50^*	27K	Feb 9, 2022	Direct	F1
transaction	CERE	Common Stock	Sale	-$750K	-25K	-92.66%	$30.00	1.98K	Feb 9, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-25K	-6.74%	$0.00	346K	Feb 9, 2022	Common Stock	25K	$3.50	Direct	F1, F2
transaction	CERE	Stock Option (Right to Buy)	Award	$0	+169K		$0.00	169K	Feb 9, 2022	Common Stock	169K	$30.36	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F3	25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter.